Tilray (TLRY) Receives News Sentiment Rating of 0.10
News coverage about Tilray (NASDAQ:TLRY) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tilray earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.474053880471 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- $10.00 Million in Sales Expected for Tilray Inc (TLRY) This Quarter (americanbankingnews.com)
- Tilray shares recover after downgrade by Northland Capital Markets (proactiveinvestors.com)
- Tilray’s Market Cap Will Soon Be Larger Than Aphria And Aurora Cannabis Combined (seekingalpha.com)
- Namaste Signs Cannabis Purchase Agreement With Tilray® (markets.businessinsider.com)
- Tilray Flying Too High (seekingalpha.com)
Several equities analysts have commented on TLRY shares. Roth Capital started coverage on shares of Tilray in a research note on Tuesday, August 14th. They issued a “buy” rating and a $35.00 price target for the company. Cowen started coverage on shares of Tilray in a research note on Monday, August 13th. They issued an “outperform” rating and a $34.00 price target for the company. Finally, Northland Securities downgraded shares of Tilray from an “outperform” rating to a “market perform” rating in a research note on Thursday.
Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, August 28th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.08). The business had revenue of $9.70 million for the quarter, compared to analyst estimates of $9.01 million. Tilray’s quarterly revenue was up 94.0% on a year-over-year basis. sell-side analysts expect that Tilray will post -0.45 EPS for the current fiscal year.
In other Tilray news, CRO Edward Wood Pastorius, Jr. purchased 14,705 shares of the company’s stock in a transaction on Monday, July 23rd. The stock was acquired at an average price of $17.00 per share, for a total transaction of $249,985.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brendan Kennedy purchased 14,706 shares of the company’s stock in a transaction on Monday, July 23rd. The stock was acquired at an average price of $17.00 per share, with a total value of $250,002.00. The disclosure for this purchase can be found here.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Recommended Story: Asset Allocation and Your Retirement
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.